Florida Cancer Centers First To Implement Sicel Technologies, Inc.'s DVS(R) Implantable Radiation Sensor In The Treatment Of Breast And Prostate Cancer

RALEIGH N.C.--(BUSINESS WIRE)--Aug. 29, 2006--Sicel Technologies, Inc. announced today that physicians at Boca Raton Community Hospital's Lynn Cancer Institute and Melbourne Internal Medical Associates (MIMA) Cancer Center are the first to incorporate the Company's DVS(R) (Dose Verification System) into their treatment protocols. DVS(R) is the first permanently implantable, wireless, telemetric radiation sensor for human use to be commercially available in the United States. Using the hand-held reader, physicians are able to determine after each treatment session the actual dose of radiation being delivered to the tumor and normal tissue.